Soligenix (SNGX) Stock Price, News & Analysis

Company Overview

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Key Stats

• Today's Range: $2.49 to $2.99
• 50-Day Range: $1.12 to $3.29
• 52-Week Range: $1.09 to $5.40
• Volume: 789,027 shs
• Average Volume: 3.36 million shs
• Market Capitalization: $9.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Soligenix Stock Analysis - MarketRank™

Soligenix scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Soligenix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Soligenix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Soligenix are expected to grow in the coming year, from ($4.65) to ($2.93) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Soligenix is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Soligenix is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Soligenix has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.40% of the float of Soligenix has been sold short.

Short Interest Ratio / Days to Cover

Soligenix has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Soligenix has recently increased by 16.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Soligenix does not currently pay a dividend.

Dividend Growth

Soligenix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.40% of the float of Soligenix has been sold short.

Short Interest Ratio / Days to Cover

Soligenix has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Soligenix has recently increased by 16.73%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.26

News Sentiment

Soligenix has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Soligenix this week, compared to 1 article on an average week.

Search Interest

16 people have searched for SNGX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

2 people have added Soligenix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Soligenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.05% of the stock of Soligenix is held by insiders.

Percentage Held by Institutions

Only 3.60% of the stock of Soligenix is held by institutions.

SNGX Stock Analysis - Frequently Asked Questions

How have SNGX shares performed this year?

Soligenix's stock was trading at $2.69 at the beginning of the year. Since then, SNGX stock has increased by 9.3% and is now trading at $2.94.

How were Soligenix's earnings last quarter?

Soligenix Inc. (NASDAQ:SNGX) released its quarterly earnings data on Thursday, August, 14th. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.79) by $0.03.

When did Soligenix's stock split?

Shares of Soligenix reverse split on the morning of Thursday, June 6th 2024.The 1-16 reverse split was announced on Thursday, June 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Who are Soligenix's major shareholders?

Soligenix's top institutional shareholders include Connective Capital Management LLC (3.67%).
View institutional ownership trends.

How do I buy shares of Soligenix?

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Soligenix investors own include Tonix Pharmaceuticals (TNXP), Trevena (TRVN), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), T2 Biosystems (TTOO), iBio (IBIO) and Dynavax Technologies (DVAX).

Company Calendar

• Today: 8/14/2025
• Last Earnings: 8/14/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNGX
• CIK: 812796
• Web: www.soligenix.com
• Phone: (609) 538-8200
• Fax: 609-452-6467
• Employees: 20
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Soligenix: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +104.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.27 million
• Net Margins: N/A
• Pretax Margin: -499,900.00%
• Return on Equity: -223.89%
• Return on Assets: -103.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.85
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: -$117.03 thousand
• Price / Sales: -82.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.64 per share
• Price / Book: 1.79

Miscellaneous

• Outstanding Shares: 3,264,000
• Free Float: 3,164,000
• Market Cap: $9.60 million
• Optionable: Not Optionable
• Beta: 1.95